CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Docetaxel and Hormone Treatment compared to Hormone Treatment alone in people with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response (TRIPLE-SWITCH)
Congrats to CCTG investigator Biniam Kidane for his recognition award, the Aubie Angel Young Investigator Award in Clinical Research: This represents the University of Manitoba’s highest award for young faculty members who have attained a national and international reputation in their research accomplishments.
CommNETs and NANETS Guidelines for the Diagnosis and Management of Patients with Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 ENETS Expert Consensus Guidelines
The Canadian Cancer Trials Group (CCTG) is pleased to announce that our Director, Dr. Janet Dancey, has been elected to the Canadian Academy of Health Sciences (CAHS), which represents Canadian health sciences internationally and informs solutions that improve the health of all Canadians.
Publication for BL12: A Multicentre Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients with Advanced Urothelial Cancer Progressing on or after a Platinum Containing Regimen
The results for the CCTG PA7 trial were recently presented at the European Society for Medical Oncology (ESMO) virtual Congress. The CCTG lead for this study, Dr. Daniel Renouf, reported on key results of the PA7 Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma Randomized Phase II Study of Gemcitabine (GEM) and Nab-Paclitaxel (Nab-P) vs. GEM, Nab-P, Durvalumab (D) and Tremelimumab (T) as First Line study.
CCTG would like to extend condolences to the family, friends, and colleagues of Dr. Libni Joseph Eapen who passed suddenly last week. Dr. Eapen was a researcher and radiation oncologist at the Ottawa Cancer Centre for the entirety of his career, he dedicated his 66 years to learning, teaching, humour and healing.
Condolences can be left on his obituary page https://www.dignitymemorial.com/obituaries/ottawa-on/libni-eapen-9358605
